Trial Site Detail

 

Drug:
PDR001
Trial:
Phase I/II Study of PDR001 in Patients With Advanced Malignancies
Conditions: Solid Tumors
Trial Status:
Active, not recruiting

 

Sarah Cannon Research Institute

3322 West End Avenue     Suite 900
Nashville , TN 37203
USA

 

Principal Investigator:
Howard A. Burris, III MD
Contact:
Activation Status of this Site:
Closed
Notes about this Site:
Sarah Cannon Research Institute Website:
http://www.sarahcannonresearch.com/CustomPage.asp?PageName=Refractory%20Malignancies

 

 

Navigating the Map

Use the plus (+) and minus (-) controls to zoom in/out.

Click and drag the map or use the arrows to move (pan) the map.

Tip: Click the marker before zooming and the map will stay centered on the marker as you zoom.